NO996205D0 - Behandling av insulinresistens med veksthormonutskillelsesmiddel - Google Patents

Behandling av insulinresistens med veksthormonutskillelsesmiddel

Info

Publication number
NO996205D0
NO996205D0 NO996205A NO996205A NO996205D0 NO 996205 D0 NO996205 D0 NO 996205D0 NO 996205 A NO996205 A NO 996205A NO 996205 A NO996205 A NO 996205A NO 996205 D0 NO996205 D0 NO 996205D0
Authority
NO
Norway
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
NO996205A
Other languages
English (en)
Norwegian (no)
Other versions
NO996205L (no
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO996205L publication Critical patent/NO996205L/no
Publication of NO996205D0 publication Critical patent/NO996205D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO996205A 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel NO996205D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO996205L NO996205L (no) 1999-12-15
NO996205D0 true NO996205D0 (no) 1999-12-15

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996205A NO996205D0 (no) 1997-06-25 1999-12-15 Behandling av insulinresistens med veksthormonutskillelsesmiddel

Country Status (41)

Country Link
US (3) US6448263B1 (ru)
EP (1) EP1000085B1 (ru)
JP (2) JP2000514099A (ru)
KR (1) KR20010014224A (ru)
CN (2) CN1152049C (ru)
AP (1) AP1145A (ru)
AR (1) AR012256A1 (ru)
AT (1) ATE305477T1 (ru)
AU (1) AU747510B2 (ru)
BG (1) BG104008A (ru)
BR (1) BR9810477A (ru)
CA (1) CA2294464A1 (ru)
CO (1) CO4950621A1 (ru)
DE (1) DE69831745T2 (ru)
DZ (1) DZ2539A1 (ru)
EA (1) EA002089B1 (ru)
EG (1) EG21712A (ru)
ES (1) ES2248899T3 (ru)
HK (1) HK1028051A1 (ru)
HN (1) HN1998000088A (ru)
HR (1) HRP980361A2 (ru)
HU (1) HUP0001922A3 (ru)
ID (1) ID24345A (ru)
IL (7) IL154116A0 (ru)
IN (1) IN189724B (ru)
IS (1) IS5275A (ru)
MA (1) MA24581A1 (ru)
NO (1) NO996205D0 (ru)
NZ (1) NZ500655A (ru)
OA (1) OA11242A (ru)
PA (1) PA8452601A1 (ru)
PE (1) PE105399A1 (ru)
PL (1) PL337659A1 (ru)
SK (1) SK175699A3 (ru)
TN (1) TNSN98113A1 (ru)
TR (1) TR199903257T2 (ru)
TW (1) TW553943B (ru)
UA (1) UA64751C2 (ru)
WO (1) WO1998058949A1 (ru)
YU (1) YU70199A (ru)
ZA (1) ZA985546B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (ru) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Translated By PlajЛЕЧЕНИЕ ИНСУЛИНОВОЙ ТОЛЕРАНТНОСТИ ВЕЩЕСТВАМИ, КОТОРЫЕ УСИЛИВАЮТ СЕКРЕЦИЮ ГОРМОНА РОСТА
UA53716C2 (ru) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратная соль замещенного дипептида в качестве средства, стимулирующего секрецию гормона роста
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
BRPI0519728B1 (pt) * 2004-12-21 2016-12-13 Hercules Inc resinas catiônicas reativas e processo de fabricação de papel
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
WO2014192294A1 (en) * 2013-05-28 2014-12-04 Raqualia Pharma Inc. Polymorph forms
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
TWI724995B (zh) * 2014-08-05 2021-04-21 日商拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之絲胺酸衍生物
EP3212648A1 (en) * 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
WO1994011012A1 (en) 1992-11-06 1994-05-26 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
ATE424412T1 (de) 1995-12-22 2009-03-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (ru) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратная соль замещенного дипептида в качестве средства, стимулирующего секрецию гормона роста
UA64751C2 (ru) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Translated By PlajЛЕЧЕНИЕ ИНСУЛИНОВОЙ ТОЛЕРАНТНОСТИ ВЕЩЕСТВАМИ, КОТОРЫЕ УСИЛИВАЮТ СЕКРЕЦИЮ ГОРМОНА РОСТА

Also Published As

Publication number Publication date
AU747510B2 (en) 2002-05-16
AR012256A1 (es) 2000-09-27
IL154111A0 (en) 2003-07-31
ATE305477T1 (de) 2005-10-15
HN1998000088A (es) 1999-01-08
DE69831745D1 (de) 2006-02-09
PA8452601A1 (es) 2000-05-24
IL156465A (en) 2004-07-25
HUP0001922A3 (en) 2001-02-28
HK1028051A1 (en) 2001-02-02
WO1998058949A1 (en) 1998-12-30
MA24581A1 (fr) 1998-12-31
IL154115A0 (en) 2003-07-31
TNSN98113A1 (fr) 2005-03-15
AU7445698A (en) 1999-01-04
JP2000514099A (ja) 2000-10-24
PL337659A1 (en) 2000-08-28
CO4950621A1 (es) 2000-09-01
ES2248899T3 (es) 2006-03-16
JP3742643B2 (ja) 2006-02-08
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
DE69831745T2 (de) 2006-08-31
CA2294464A1 (en) 1998-12-30
US6448263B1 (en) 2002-09-10
US6630487B2 (en) 2003-10-07
NO996205L (no) 1999-12-15
NZ500655A (en) 2002-02-01
IS5275A (is) 1999-11-26
EP1000085A1 (en) 2000-05-17
US6867202B1 (en) 2005-03-15
HRP980361A2 (en) 1999-02-28
EG21712A (en) 2002-02-27
ZA985546B (en) 2000-01-10
EP1000085B1 (en) 2005-09-28
BG104008A (en) 2000-07-31
IL154114A0 (en) 2003-07-31
SK175699A3 (en) 2001-04-09
ID24345A (id) 2000-07-13
IL156465A0 (en) 2004-01-04
IL154116A0 (en) 2003-07-31
EA002089B1 (ru) 2001-12-24
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
UA64751C2 (ru) 2004-03-15
YU70199A (sh) 2003-01-31
BR9810477A (pt) 2007-05-22
PE105399A1 (es) 1999-11-04
CN1152049C (zh) 2004-06-02
AP1145A (en) 2003-02-14
CN1259140A (zh) 2000-07-05
EA199901075A1 (ru) 2000-08-28
OA11242A (en) 2003-07-23
US20030100561A1 (en) 2003-05-29
TW553943B (en) 2003-09-21
IN189724B (ru) 2003-04-19
KR20010014224A (ko) 2001-02-26
DZ2539A1 (fr) 2003-02-08
JP2005097261A (ja) 2005-04-14
CN1530107A (zh) 2004-09-22
TR199903257T2 (xx) 2000-12-21

Similar Documents

Publication Publication Date Title
NO996205L (no) Behandling av insulinresistens med veksthormonutskillelsesmiddel
FI963482A0 (fi) Menetelmä hematopoieesin stimuloimiseksi hemoglobiinilla
NO973446D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69837264D1 (de) Dipeptidderivate zur förderung der sekretion von wachstumshormon
DK0885961T3 (da) Hidtil ukendte insulinderivater med hurtig indtræden af virkning
EP0741578A4 (en) HUMAN GROWTH HORMONE
DE69835103D1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69731979D1 (de) Dialysekatheter mit starren und kollabierbaren lumina
NO20001242D0 (no) April - et nytt protein med veksteffekter
DE69527672T2 (de) Schiene zur Korrektur des Fusses und Schuhwerk mit dieser Schiene
EE200100479A (et) Kasvuhormooni nõristitena kasulikud heterotsüklilised aromaatsed ühendid ja nende kasutamine
PL338883A1 (en) Growth hormone secretion stimulating compounds
NO991186D0 (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
NO975992L (no) Forbindelser med veksthormonfrigjörende egenskaper
DE69309698D1 (de) Hautbehandlung mit adhäsionsverstärkenden eigenschaften
PL329851A1 (en) Treatment of diseases associated with vegf
DK0907358T3 (da) Behandling med ensartet afgivelse af lægemiddel
ZA987383B (en) Treatment of congestive heart failure with growth hormone secretagogues.
NO975718L (no) Behandling av insulinresistens
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
NO996265L (no) Behandling av diabetes med rosiglitazon og insulin
AU7609298A (en) Treatment of heart failure with growth hormone
HK1042253A1 (zh) 化合物及其用於治療糖尿病並發症的用途

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application